Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$1.7M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$266M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Ma Songjiang | Jan 17, 2025 | Sell | 2,000 | $10.72 | $21,000 |
| Ma Songjiang | Jan 15, 2025 | Sell | 2,000 | $10.85 | $22,000 |
| Ma Songjiang | Jan 13, 2025 | Sell | 56 | $10.1 | $570 |
| Ma Songjiang | Jan 10, 2025 | Sell | 1,057 | $10.02 | $11,000 |
| Ma Songjiang | Jan 7, 2025 | Sell | 1,275 | $10.02 | $13,000 |
| Ma Songjiang | Jan 6, 2025 | Sell | 941 | $10.16 | $9,600 |
| Ma Songjiang | Jan 3, 2025 | Sell | 1,167 | $11.03 | $13,000 |
| Ma Songjiang | Jan 3, 2025 | Sell | 833 | $11.85 | $9,900 |
| Ma Songjiang | Jan 2, 2025 | Sell | 2,000 | $12.4 | $25,000 |
| Ma Songjiang | Dec 31, 2024 | Sell | 2,000 | $12.3 | $25,000 |
| Ma Songjiang | Dec 27, 2024 | Sell | 2,000 | $12.58 | $25,000 |
| Ma Songjiang | Dec 26, 2024 | Sell | 1,644 | $12.62 | $21,000 |
| Ma Songjiang | Dec 26, 2024 | Sell | 356 | $13.05 | $4,600 |
| Ma Songjiang | Dec 24, 2024 | Sell | 2,000 | $11.93 | $24,000 |
| Ma Songjiang | Dec 23, 2024 | Sell | 1,704 | $12.24 | $21,000 |
| Ma Songjiang | Dec 23, 2024 | Sell | 296 | $12.44 | $3,700 |
| Ma Songjiang | Dec 20, 2024 | Sell | 2,000 | $10.9 | $22,000 |
| Ma Songjiang | Dec 18, 2024 | Sell | 1,571 | $11.17 | $18,000 |
| Ma Songjiang | Dec 18, 2024 | Sell | 429 | $12.11 | $5,200 |
| Ma Songjiang | Dec 17, 2024 | Sell | 1,212 | $10.94 | $13,000 |
| Ma Songjiang | Dec 17, 2024 | Sell | 788 | $11.23 | $8,800 |
| USMAN NASSIM | Jun 28, 2024 | Sell | 3,452 | $12.004 | $41,000 |
| USMAN NASSIM | May 1, 2024 | Sell | 14,900 | $13.86 | $210,000 |
| USMAN NASSIM | May 1, 2024 | Sell | 5,000 | $14.9 | $75,000 |
| USMAN NASSIM | May 1, 2024 | Sell | 100 | $15.63 | $1,600 |
| USMAN NASSIM | Apr 1, 2024 | Sell | 20,000 | $16.15 | $320,000 |
| USMAN NASSIM | Mar 15, 2024 | Sell | 20,000 | $17.26 | $350,000 |
| Ma Songjiang | Jan 3, 2024 | Sell | 833 | $11.85 | $9,900 |
What's the latest insider transaction for Gyre Therapeutics?
The most recent insider transaction for Gyre Therapeutics was conducted by Ma Songjiang, who sold 2,000 shares on January 17, 2025 at a price of $10.72 per share.
Which insider has sold the most GYRE stock over the last two years?
USMAN NASSIM has sold the most GYRE stock in the last 2 years, with a total value of $990,000.
What is the total value of insider transactions for Gyre Therapeutics (GYRE) in the last 2 years?
The total value of insider transactions for Gyre Therapeutics in the last 2 years is negative, amounting to -$1.3M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Gyre Therapeutics' market confidence?
Over the last 2 years, insider transactions for Gyre Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
